Abstract
BackgroundMetastatic colorectal cancer (mCRC) is a major cause of death of malignant tumor and the valuable prognostic biomarker for chemotherapy is crucial in decreasing mortality. Previous studies have proved the prognostic value of the mean platelet volume (MPV) in survival of primary operable CRC patients. However, the prognostic impact of MPV in mCRC is still unclear. In this study, we aimed to clarify the prognostic role of MPV in mCRC undergoing standard first-line chemotherapy.MethodsFrom January 2012 to December 2016, we conducted a retrospective clinical study included 264 mCRC patients (NCT03532711). All the enrolled patients received the standard oxaliplatin-based or irinotecan-based chemotherapy. The association between the baseline MPV and clinicopathological features were examined.ResultsUnivariate analysis revealed that decreased MPV, the platelet counts (PLT), platelet-to-lymphocyte ratio (PLR) and the platelet crit (PCT) were significantly associated with inferior overall survival (OS) (p < 0.05). On multivariate analysis, elevated PLR was significant prognostic factors for OS, with hazard ratios of (HR:1.006, 95% CI:1.001–1.011, p = 0.01) while MPV was not, respectively (p < 0.05).ConclusionsOur study demonstrated that the baseline MPV level may act as a predictive factor for survival in mCRC patients undergoing standard chemotherapy.Trial registrationThis study was retrospectively registered in date May the 20th 2018. The registration number (TRN) of this study was NCT03532711.
Highlights
Metastatic colorectal cancer is a major cause of death of malignant tumor and the valuable prognostic biomarker for chemotherapy is crucial in decreasing mortality
Our results suggested that the combination of SNPs may predict the therapeutic efficacy of the first-line chemotherapy for Metastatic colorectal cancer (mCRC) patients [4]
It is showed that mean platelet volume (MPV) predicted cancer prognosis with a sensitivity of 0.625 and a specificity of 0.272 (AUC = 0.473, 95% CI: 0.402–0.544, p = 0.459)
Summary
Metastatic colorectal cancer (mCRC) is a major cause of death of malignant tumor and the valuable prognostic biomarker for chemotherapy is crucial in decreasing mortality. We aimed to clarify the prognostic role of MPV in mCRC undergoing standard first-line chemotherapy. Colorectal cancer (CRC) is the third most common malignancies in males and second most common in females worldwide. Standard chemotherapy remains the most effective therapy for patients with metastatic colorectal cancer (mCRC) [2]. There is an urgency to develop reliable prognostic biomarkers for mCRC patients receiving standard chemotherapy. One of our published paper indicated that patients carrying several SNP combinations may benefit more from the first-line chemotherapy such as FOLFOX/XELOX regimen. Our results suggested that the combination of SNPs may predict the therapeutic efficacy of the first-line chemotherapy for mCRC patients [4]. We aimed to identify prognostic mCRC biomarkers that are low-cost and obtainable via routine blood counts
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
